A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Juan-Miguel CejalvoWolfgang JacobTania Fleitas KanonnikoffEnriqueta FelipAlejandro Navarro MendivilMaria Martinez-GarcíaAlvaro Taus GarciaNatasha LeighlUlrik LassenMorten Mau-SoerensenCeline AdessiFrancesca MichielinIan JamesMaurizio CeppiMax HasmannMartin WeisserAndres Cervantes

Published in: ESMO open (2019)

Lumretuzumab in combination with carboplatin and paclitaxel was well tolerated. Objective responses were enriched in tumours expressing higher heregulin mRNA levels.

Keyphrases

phase ii study
squamous cell carcinoma
small cell lung cancer
phase iii
randomized controlled trial
clinical trial
low grade
open label
binding protein
drug delivery
chemotherapy induced
rectal cancer
double blind